Moolec Science (MLECW) Cost of Revenue (2022 - 2024)
Moolec Science (MLECW) posted Cost of Revenue of $3.3 million for Q4 2024, up 115.1% sequentially from $1.5 million in Q3 2024, and up 16453.56% YoY from N/an in Q1 2024.
Moolec Science (MLECW) Cost of Revenue (2022 - 2024) Analysis & Trends
Moolec Science has reported Cost of Revenue for 3 years, with the latest figure at $3.3 million in Q4 2024.
- Quarterly Cost of Revenue rose 16453.56% year-over-year to $3.3 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $8.5 million (up 232.48% YoY) and the FY2024 annual result came in at $5.2 million, up 391.49% from the prior year.
- Cost of Revenue improved to $3.3 million in Q4 2024 per MLECW's latest filing, from $1.5 million in the prior quarter.
- Over five years, Cost of Revenue peaked at $3.3 million in Q4 2024 and troughed at $5455.0 in Q1 2022.
- A 3-year average of $923968.4 and a median of $507953.0 in 2022 frame the typical range for Cost of Revenue.
- The sharpest annual moves came in 2023 and 2024: Cost of Revenue dropped 2.11% in 2023, then jumped 16453.56% in 2024.
- Over 3 years, Cost of Revenue stood at $20473.0 in 2022, then slipped by 2.11% to $20040.0 in 2023, then surged by 16453.56% to $3.3 million in 2024.
- According to Business Quant data, Cost of Revenue over the past three periods registered $3.3 million, $1.5 million, and $1.6 million for Q4 2024, Q3 2024, and Q2 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 93.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 174.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 298.26 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 387.98 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 67.21 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 3.32 Mn |
| Dec 31, 2024 | 3.32 Mn |
| Sep 30, 2024 | 1.54 Mn |
| Sep 30, 2024 | 1.54 Mn |
| Jun 30, 2024 | 1.59 Mn |
| Jun 30, 2024 | 1.59 Mn |
| Mar 31, 2024 | 2.02 Mn |
| Mar 31, 2024 | 2.02 Mn |
| Dec 31, 2023 | 20,040.00 |
| Dec 31, 2023 | 20,040.00 |
| Sep 30, 2023 | 1.52 Mn |
| Sep 30, 2023 | 1.52 Mn |
| Jun 30, 2023 | 994,199.00 |
| Jun 30, 2023 | 994,199.00 |
| Mar 31, 2023 | 14,364.00 |
| Mar 31, 2023 | 14,364.00 |
| Dec 31, 2022 | 20,473.00 |
| Dec 31, 2022 | 20,473.00 |
| Sep 30, 2022 | 19,318.00 |
| Sep 30, 2022 | 19,318.00 |